-
-
Humanized model of the immune system
-
iHuPBMC-T
-
iHuPBMC-NK
-
iHuPBMC-B
-
PBMC-LT
-
CD34+ HSC
-
Winn model
-
iHuPBMC-MHC/KO
-
iHuPBMC-OncVax
-
PBMC mixed inoculation model
more -
-
In vivo tumor experimental platform
-
CDX
-
iHuPDX
-
Non-GLP Toxicology
-
PK/PD
-
Brain in situ model
-
Other in situ models
-
Hematologic tumor model system inoculation
-
Creation of high interstitial tumor models
more -
-
In vitro killing experiment platform
-
Immune co-culture killing model
-
CDC
-
In vitro killing experiment platform
-
IC50
-
PDC High-Throughput In Vitro Pharmacodynamics
-
3D organoids
-
ADCC
-
T cell-mediated killing experiment
more -
-
Mouse-derived immune system model
more -
Tumor vaccine
more -
Cell therapy
more -
In vitro testing platform
more -
Non-GLP Toxicology Platform
more -
Non-tumor model and drug efficacy evaluation platform
-
Systematic Vaccination Model
-
Non-tumor model and drug efficacy evaluation platform
-
Skin injury model
-
Stroke model
-
Liver fibrosis model
-
Diabetes model
-
Gouty Arthritis (GA) Model
-
Pulmonary fibrosis model
-
Systemic lupus erythematosus (SLE) model
-
Inflammatory Bowel Disease (IBD) model
-
Rheumatoid Arthritis (RA) Model
more -
-
-
-
PDX model
-
PDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
CDX model
-
CDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
Homogeneous Model
-
Homogeneous Model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Breast cancer
-
Stomach cancer
-
Liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Pancreatic cancer
-
Kidney cancer
-
Bladder cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer
-
Ovarian cancer
-
Esophageal cancer
-
Skin cancer
-
sarcoma
-
Nervous System Cancer
-
Embryonal carcinoma
-
Lymphoma
-
Leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other
-
Colorectal cancer
more -
-
News Center
——
InnoModels Biotechnology: What are the features of the iHuPBMC-T platform?
Author:
InnoModels
Release time:
2024-05-31
In the field of biomedicine, accurate simulation of the human physiological environment is crucial to the success of scientific research experiments. Especially in tumor and tumor immunology research, the simulation and reconstruction of the complex human immune system is the key to promoting the innovation of disease treatment methods. Against this background, iHuPBMC-T platform launched by InnoModels Biotechnology, with its unique technological advantages and innovativeness, provides powerful support for T-cell immunotherapy research.
The iHuPBMC-T platform is an innovative platform focusing on T-cell immunotherapy research and development, which is elaborated by InnoModels Biotechnology. The core of the platform lies in its ability to accurately simulate the behavior of human T-cells in the tumor microenvironment, thus providing researchers with a realistic and reliable experimental environment. This is important for exploring the interactions between T cells and tumor cells, as well as optimizing the efficacy and safety of T cell immunotherapy.
It is worth mentioning that the iHuPBMC-T platform has successfully solved the major challenges of tumor growth and PBMC (peripheral blood mononuclear cells) antagonism and cycle matching in immune system tumor models. In the past, this challenge has been a major constraint to the progress of tumor immunology research. However, through the technological innovation and optimization of InnoModels Biotechnology, the platform achieves the simultaneous growth of tumor cells and PBMCs, which greatly improves the operability and success rate of the experiment.

In addition, the iHuPBMC-T platform demonstrates excellent compatibility. It is compatible with most tumor cells, which means that researchers can carry out experiments in a wide range of tumor types and explore the wide application of T-cell immunotherapy. What's more, the platform can select a suitable donor from multiple PBMC donors in a single pre-experiment to co-construct and formalize experiments with tumor cells, which undoubtedly saves researchers a lot of time and cost.
In addition to the technical advantages, the iHuPBMC-T platform also demonstrates a high degree of stability and reliability. Through the accurate modeling technology of InnoModels Biotechnology, the platform is able to reconstruct a wide range of immune cells in a stable manner, thus ensuring the accuracy and reproducibility of experimental results. At the same time, the platform also improves the modeling success rate of experiments, making the results more reliable and stable.
Overall, the iHuPBMC-T platform of InnoModels Biotechnology provides powerful support for T-cell immunotherapy research with its unique technical advantages and innovativeness. The platform has not only solved the problems that existed in past studies, but also demonstrated excellent compatibility and stability. In the future, with the continuous development of the biomedical field, the iHuPBMC-T platform is expected to provide assistance for the innovation of treatment methods for more diseases and promote the progress of human health.
InnoModels Biotechnology (Beijing) Co., Ltd.
-
TEL: +86 15711355061
-
E-mail: xuyl@imodels.tech
-
Address: Building 14, No. 79 West Shuangying Road, Changping District, Beijing
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.
These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.
These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.
These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.
InnoModels Biotechnology (Beijing) Co., Ltd